| MACHOVÁ POLÁKOVÁ, Kateřina, Václava POLÍVKOVÁ, Jana RULCOVÁ, Hana KLAMOVÁ, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Zdeněk POSPÍŠIL, Jiří MAYER and Jana MORAVCOVÁ. Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. Experimental hematology. Netherlands: Elsevier Science Inc, 2010, vol. 38, No 1, p. 20-26. ISSN 0301-472X. |
Other formats:
BibTeX
LaTeX
RIS
@article{869378,
author = {Machová Poláková, Kateřina and Polívková, Václava and Rulcová, Jana and Klamová, Hana and Jurček, Tomáš and Dvořáková, Dana and Žáčková, Daniela and Pospíšil, Zdeněk and Mayer, Jiří and Moravcová, Jana},
article_location = {Netherlands},
article_number = {1},
keywords = {BCR-ABL; CML; imatinib},
language = {eng},
issn = {0301-472X},
journal = {Experimental hematology},
title = {Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.},
volume = {38},
year = {2010}
}
TY - JOUR
ID - 869378
AU - Machová Poláková, Kateřina - Polívková, Václava - Rulcová, Jana - Klamová, Hana - Jurček, Tomáš - Dvořáková, Dana - Žáčková, Daniela - Pospíšil, Zdeněk - Mayer, Jiří - Moravcová, Jana
PY - 2010
TI - Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.
JF - Experimental hematology
VL - 38
IS - 1
SP - 20-26
EP - 20-26
PB - Elsevier Science Inc
SN - 0301472X
KW - BCR-ABL
KW - CML
KW - imatinib
N2 - OBJECTIVE: Of 140 chronic myeloid leukemia patients responding to imatinib with complete cytogenetic remission, 32 exhibited a plateau of BCR-ABL values at >or=0.1% level in a minimum of three subsequent samples (minimal duration, 6 - 9 months). Median follow-up of unchanged BCR-ABL transcript level was 12 months (range, 6 - 64). We tested this group of patient for BCR-ABL mutations to reveal resistance development and to evaluate the risk of disease progression. RESULTS: Mutation was detected by direct sequencing in 9 of 32 patients (28%). Loss of complete cytogenetic remission or 1 log rise of BCR-ABL was observed in five of nine patients at a median of 5 months (range, 4-17) since first detection of mutation. One patient with no mutation relapsed 12 months after the start of the BCR-ABL plateau. In 5 of 32 patients without mutation (16%), BCR-ABL level significantly decreased after the first plateau to levels that stayed unchanged for a median of 11 months (range, 7-28).
ER -
MACHOVÁ POLÁKOVÁ, Kateřina, Václava POLÍVKOVÁ, Jana RULCOVÁ, Hana KLAMOVÁ, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Zdeněk POSPÍŠIL, Jiří MAYER and Jana MORAVCOVÁ. Constant BCR-ABL transcript level \&{}gt;or=0.1\%{} (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. \textit{Experimental hematology}. Netherlands: Elsevier Science Inc, 2010, vol.~38, No~1, p.~20-26. ISSN~0301-472X.
|
